Myrbetriq regulatory update

EMA's CHMP recommended approval of an MAA from Astellas for Betmiga mirabegron from Astellas to treat overactive bladder (OAB). In June, FDA approved the adrenergic receptor beta 3 ( ADRB3) agonist a...